Try our beta test site

Safety and Efficacy of APD356 in the Treatment of Obesity

This study has been completed.
Information provided by:
Arena Pharmaceuticals Identifier:
First received: March 1, 2005
Last updated: February 1, 2010
Last verified: December 2006

This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.

The purpose of this study is to obtain preliminary assessment of the safety and efficacy of APD356, when administered daily for 28 days, in obese subjects who are otherwise healthy.

Condition Intervention Phase
Drug: APD356
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 4-Week, Dose-ranging, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of APD356 in Obese Patients

Resource links provided by NLM:

Further study details as provided by Arena Pharmaceuticals:

Primary Outcome Measures:
  • Change in body weight

Secondary Outcome Measures:
  • Safety
  • Changes in waist circumference, hip circumference and waist/hip ratio

Estimated Enrollment: 400
Study Start Date: December 2004
Estimated Study Completion Date: May 2005
Detailed Description:
This is a double-blind, placebo-controlled, randomized, parallel group study. Three different doses of APD356 or placebo will be administered daily for 28 days, to uncomplicated obese, male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects will be enrolled.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
  • Healthy male or nonpregnant, nonlactating females aged between 18 and 65 years (inclusive)
  • Body Mass Index (BMI) of 30-45 Kg/m^2.
  • Non-smoker
  • No concomitant medications
  • No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00104507

United States, Louisiana
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808
Sponsors and Collaborators
Arena Pharmaceuticals
Study Chair: William R Shanahan, Jr, MD Arena Pharmaceuticals
  More Information

Additional Information: Identifier: NCT00104507     History of Changes
Other Study ID Numbers: APD356-003
Study First Received: March 1, 2005
Last Updated: February 1, 2010

Keywords provided by Arena Pharmaceuticals:
Appetite suppressant
Weight Loss

Additional relevant MeSH terms:
Nutrition Disorders
Body Weight
Signs and Symptoms processed this record on March 30, 2017